Ionis Pharmaceuticals, Inc partner, GSK plc, announced that the FDA has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide… read more.
Mirum Pharmaceuticals, Inc. announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older… read more.
Novo Nordisk presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver… read more.
According to the EMA website, on 23 July 2026, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Lynavoy, intended… read more.
AbbVie announced that the European Commission approved Maviret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C viru infection in adults and… read more.
Metabolic dysfunction‑associated fatty liver disease (MAFLD) is a leading chronic liver disease in China, yet primary care capacity remains limited. To address this, the first national Guidelines for Diagnosis… read more.
The American Gastroenterological Association (AGA) today announced the launch of Nigel, an artificial intelligence (AI)-powered virtual assistant developed exclusively for gastroenterology and hepatology. Built using AGA’s trusted clinical guidance and developed in collaboration… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved a semaglutide injection (Wegovy) to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis… read more.
NICE(UK): Seladelpar can be used, within its marketing authorisation, as an option to treat primary biliary cholangitis, including associated pruritus, in adults. It can be used: i) with… read more.
Pre-retrieval imaging is moving liver transplantation toward a more precise and less invasive era. A new evidence synthesis shows how ultrasound, computed tomography, and magnetic resonance imaging can… read more.
The MHRA has authorised the medicine resmetirom (Rezdiffra) to treat adult patients with metabolic dysfunction-associated steatohepatitis (MASH). In patients with MASH, a protein called thyroid hormone receptor beta… read more.
Roche announced the launch of its comprehensive Liver Disease Panel, a suite of certified algorithms designed to help clinicians better identify and manage chronic liver disease (CLD). By… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
